COMMUNIQUÉS West-GlobeNewswire

Latest Legal Anabolic Steroid Alternatives for Bodybuilding 2026: Natural Steroids for Muscle Building & Cutting Fat Introduced by CrazyBulk
04/12/2025
Legal Anabolic Steroid Alternatives for Bodybuilding from CrazyBulk in 2026: Best Selling Natural Steroids for Muscle Building and Cutting Fat. New York City, NY, Dec. 04, 2025 (GLOBE NEWSWIRE) -- In 2026, there is [...]
GATC Health to Host Virtual KOL Event to Discuss Derisq™ AI Report: Predictive, Detailed Risk Assessment of Drug Candidates, on December 10, 2025
04/12/2025
BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, announced that it will host a virtual key [...]
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
04/12/2025
SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the commencement of a [...]
Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor
04/12/2025
Praxis confirms plans to submit the essential tremor NDA for ulixacaltamide in early 2026 BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical [...]
ImPact Biotech Presents Updated Preliminary Data from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at SUO 2025
04/12/2025
– Complete response (CR) observed in 70% (35/50) of patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) – Initial durability data shows all patients (100%) who [...]
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
04/12/2025
ARLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced that it has entered into definitive agreements for the purchase of an aggregate of 10,000,000 [...]
Human Appeal’s Pot of Gold Film Comes to Amazon Prime Video
04/12/2025
BayView Entertainment Brings Groundbreaking Film to Global Streaming Audiences MISSION VIEJO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Pot of Gold , the award winning powerful independent documentary set in the [...]
Coloplast A/S - Decisions at the Annual General Meeting 2025
04/12/2025
Today, 4 December 2025, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2024/25 was approved. Distribution of year-end dividend of [...]
Chemed Corporation to Present at the BofA Securities 2025 Virtual Home Care Conference
04/12/2025
CINCINNATI, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) today announced that it will present at the BofA Securities 2025 Virtual Home Care Conference on Tuesday, December 9, 2025, at 1:20 PM (ET). [...]
Foundation Health and Amazon Pharmacy Collaborate to Bring Real-Time Prescription Price Transparency to Patients
04/12/2025
API Integration Improves Medication Access and Empowers Patients with Expanded Fulfillment Options SAN FRANCISCO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Foundation Health, a healthcare technology company that delivers AI- [...]
Philips reiterates timing of 2026 outlook
04/12/2025
December 4, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the [...]
Tilray Releases the Ultimate 2025 Holiday Drink Gift Guide, Celebrating Seasonal Sips and Moments of Connection from Coast to Coast
04/12/2025
ATLANTA, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc., company (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and [...]
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
04/12/2025
One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment of 15 months [...]
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
04/12/2025
Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of REYOBIQ as a novel therapeutic for recurrent GBM demonstrated [...]
From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection
04/12/2025
Ra’anana, Israel , Dec. 04, 2025 (GLOBE NEWSWIRE) -- In an era where airborne threats like allergens and viruses disrupt daily life for millions, a small biotech innovator in Israel is quietly reshaping approaches to [...]
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum
04/12/2025
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced plans [...]
Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium
04/12/2025
Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card BURLINGTON, [...]
Hyperion DeFi Announces Receipt of Kinetiq Airdrop, Partnership with Native Markets, and Purchase of 150,000 Additional HYPE
04/12/2025
Receives 1,918,478.78 KNTQ in the Token Generation Event Airdrop, Plus Right to Earn Additional Yield on 28,888 HYPE Staked by the Company Partnership with Native Markets to Support Hyperliquid-Aligned USDH Stablecoin [...]
Ajax Therapeutics Presents Preclinical Data on Differentiated Efficacy Profile of AJ1-11095, a First-in-Class Type II JAK2 Inhibitor, at the American Society of Hematology Annual Meeting
04/12/2025
– Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant allele burden and bone marrow fibrosis, key markers of disease modification – – AJ1-11095 [...]

Pages